Printer Friendly

Semprus BioSciences to develop anti-biofilm endotracheal tube to reduce VAP infections with aid from US Army's ATRC fund.

M2 EQUITYBITES-November 9, 2012-Semprus BioSciences to develop anti-biofilm endotracheal tube to reduce VAP infections with aid from US Army's ATRC fund(C)2012 M2 COMMUNICATIONS http://www.m2.com

Medical device company Teleflex Incorporated (NYSE:TFX) reported on Thursday the receipt of the initial phase of a USD2.3m research grant from the US Army's Telemedicine and Advanced Technology Research Centre (TATRC) in Fort Detrick, MD.

This grant has been awarded to the company's wholly owned subsidiary, Semprus BioSciences, which plans to use the fund to support the research and development of a surface-modified endotracheal tube that combines the Semprus Sustain Technology with the delivery of antimicrobials.

The research will reportedly be conducted at Semprus' facilities in Cambridge, MA, in conjunction with the US Army Institute for Surgical Research (USAISR) at Fort Sam Houston in San Antonio, TX.

When patients requiring respiratory support are ventilated in intensive care units( ICU) for extended periods of time, bacterial adherence to the endotracheal tube is considered the first step in developing a lung infection, or ventilator-associated pneumonia (VAP), said the company.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 9, 2012
Words:189
Previous Article:Piedmont RIA invests in Syntellia.
Next Article:Balchem Corporation elects Richard A. Bendure as COO.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters